September 4: The Tape Picks Pockets — Scarcity Wins Inside Every Sector

Market regime

The Goldilocks spine still holds on paper — sticky CPI easing to 2.7%, unemployment 4.1%, VIX asleep near 14.6 — but this is no longer a whole-market story. Breadth finished the session as a truce (1,581 advancers vs 1,460 decliners, the average stock +0.18%), and the leadership tells the real story: money is no longer deciding whether to own equities, but which scarce asset within each sector to own. Large caps still edge mid-caps (+0.6% vs -0.2% on the week), yet the dispersion underneath is doing the heavy lifting.

Mega forces

1. Scarcity-value rotations, not reflation, are setting the tone. Energy leads every sector (+10% on the month, +48% over the year) as WTI holds near $85 on geopolitics and OPEC discipline; gold miners push +13% monthly as the debasement hedge floors lows. This is capital hunting pricing power in commodities while rate-sensitive growth — Real Estate -1.5% month, Consumer Discretionary -3.6% — bleeds. TSLA fell ~6% today; discretionary names are the clearest de-risking.

2. The split inside AI is now exposure-specific. The megacap software/foundation layer keeps giving back — MSFT -2.7% and GOOGL -2.3% on the week, AMZN -3% — while the compute-infrastructure layer that sells the scarcity of capacity keeps working: VRT +9% and SMCI +6.8% weekly even after SNOW's post-earnings pullback. The market is rewarding the capex sellers of capacity, not the platform aggregators whose monetization is still being argued about.

3. Broad-based biotech is finally getting a real earnings catalyst. Moderna re-rated ~170% in a month on the first-in-class Merck melanoma mRNA-vaccine win — a fundamental validation of a platform, not just trial-line momentum. Oncology and biopharma-discovery themes lead the board. Skeptics (WSJ's “hype-ahead-of-the-math”) are right that commercialization is far out, but the tape is now pricing a genuine new revenue stream rather than a binary readout.

What's working

Own scarcity of capacity and pricing power: energy producers and integrated oil, gold/silver miners, and select AI-compute-infrastructure hardware (VRT, SMCI) that sells into the capex boom. Favor genuine fundamental biotech catalysts (mRNA oncology) over trial-line speculation. Financials remain a quiet +9% year with a steepening curve to their back.

Strategy

The regime rewards intra-sector selection over index exposure. Stay long the scarcity/capex complex, trim megacap software crowding, and underweight rate-sensitive consumer discretionary and Real Estate until the 10Y (still ~4.6%) breaks decisively lower. The tape is strong where earnings are visible and scarce — that is today's north star.